{"id":"tavilermide-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Tavilermide works by antagonizing integrins, cell surface receptors that mediate adhesion between cells and the extracellular matrix. By blocking integrin function, the drug reduces the recruitment and infiltration of inflammatory cells into the eye, thereby decreasing ocular inflammation and associated tissue damage. This mechanism is particularly relevant for dry eye disease and other inflammatory ocular conditions where leukocyte infiltration plays a pathogenic role.","oneSentence":"Tavilermide is a small-molecule integrin antagonist that inhibits cell adhesion and migration by blocking integrin-mediated interactions, reducing inflammatory cell infiltration in ocular tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:41.994Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"},{"name":"Ocular inflammation"}]},"trialDetails":[{"nctId":"NCT05848128","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Mimetogen Pharmaceuticals USA, Inc.","startDate":"2023-06-28","conditions":"Dry Eye Syndromes, Dry Eye Disease, Kerato Conjunctivitis Sicca","enrollment":642},{"nctId":"NCT03925727","phase":"PHASE3","title":"Tavilermide Ophthalmic Solution for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Mimetogen Pharmaceuticals USA, Inc.","startDate":"2019-03-28","conditions":"Keratoconjunctivitis Sicca, Dry Eye","enrollment":623},{"nctId":"NCT01960010","phase":"PHASE3","title":"A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Mimetogen Pharmaceuticals USA, Inc.","startDate":"2013-10","conditions":"Dry Eye Syndromes","enrollment":403},{"nctId":"NCT02665234","phase":"PHASE3","title":"A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Mimetogen Pharmaceuticals USA, Inc.","startDate":"2016-01","conditions":"Keratoconjunctivitis Sicca","enrollment":400},{"nctId":"NCT02634853","phase":"PHASE3","title":"A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Mimetogen Pharmaceuticals USA, Inc.","startDate":"2015-12","conditions":"Keratoconjunctivitis Sicca","enrollment":429}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tavilermide ophthalmic solution","genericName":"Tavilermide ophthalmic solution","companyName":"Mimetogen Pharmaceuticals USA, Inc.","companyId":"mimetogen-pharmaceuticals-usa-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tavilermide ophthalmic solution is a protein-based medication used to treat dry eye conditions, including Dry Eye Syndromes, Keratoconjunctivitis Sicca, and Dry Eye Disease. It is administered as an ophthalmic solution, typically in a 1% concentration, and has been studied in clinical trials for its safety and efficacy in treating these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}